Apriem Advisors’s Larimar Therapeutics LRMR Stock Holding History

Apriem Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-83	Closed	-$5K	–	361
2017 Q1	$5K	Hold	83	–	–	﹤0.01%	482
2016 Q4	$3K	Hold	83	–	–	﹤0.01%	584
2016 Q3	$3K	Hold	83	–	–	﹤0.01%	510
2016 Q2	$6K	Hold	83	–	–	﹤0.01%	449
2016 Q1	$7K	Hold	83	–	–	﹤0.01%	404
2015 Q4	$6K	Buy	+83	New	+$13.3K	﹤0.01%	421

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Apriem Advisors's LRMR Position: Q2 2017 in Review

Apriem Advisors sold out of Larimar Therapeutics (LRMR) in Q2 2017, closing a stake of 83 shares — an estimated $5K sold.

Apriem Advisors first reported a position in LRMR in Q4 2015 and held it in 6 quarters. The position peaked at $7K in Q1 2016. 69 funds tracked by Wall St. Rank hold LRMR as of Q2 2017.

Apriem Advisors reported no remaining Larimar Therapeutics position as of Q2 2017 after selling out during the quarter.
Apriem Advisors sold 83 Larimar Therapeutics shares in Q2 2017, an estimated $5K.
Apriem Advisors first reported a position in Larimar Therapeutics in Q4 2015 and held it in 6 quarters.
Apriem Advisors's Larimar Therapeutics position peaked at $7K in Q1 2016.
69 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2017.

Based on Apriem Advisors's 13F filing for Q2 2017, filed 4 Aug 2017.